Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 01, 2026 1 hour, 51 minutes ago
Medical News: A large new real-world study from the Czech Republic is drawing global attention after revealing that a long-used immune-boosting drug may significantly reduce deaths from COVID-19. The medication, called inosine pranobex, has been around for decades, but researchers now say it could play a much bigger role in fighting viral infections than previously thought.
A widely available immune-boosting drug shows dramatic potential in reducing COVID-19 deaths across large populations
A Massive Nationwide Study Offers New Insights
The research analyzed health records from more than 4.6 million COVID-19 patients across the Czech Republic between 2020 and 2023. After careful matching of patients based on age, sex, underlying health conditions, vaccination status, and treatments received, the final analysis included over 67,000 patients treated with inosine pranobex and more than 135,000 comparable individuals who did not receive the drug.
The study was conducted by scientists from the Third Faculty of Medicine at Charles University in Prague, the Institute of Health Information and Statistics of the Czech Republic, the Institute for Postgraduate Medical Education in Prague, and an independent researcher.
What makes this study particularly important is its scale and real-world data. Unlike smaller clinical trials, this research reflects how treatments actually perform across an entire population.
Significant Drop in Death Rates
The findings were striking. During the earlier phase of the pandemic, before the Omicron variant became dominant, patients who received inosine pranobex had a death rate of 1.65 percent compared to 2.11 percent in those who did not receive it. This translates to a 22 percent reduction in mortality.
The benefits appeared even stronger during the Omicron period. Patients treated with the drug had a death rate of just 0.13 percent, compared to 0.35 percent in the control group. That represents a remarkable 65 percent reduction in mortality risk.
Even more impressive, the effect was strongest among patients who did not receive other advanced COVID-19 treatments such as antivirals or monoclonal antibodies. In that subgroup, the reduction in death risk reached as high as 78 percent in some analyses.
How the Drug Works in the Body
Scientists believe inosine pranobex works through several mechanisms. It enhances the activity of natural killer cells, which are crucial for identifying and destroying virus-infected cells. It also stimulates T-cells and boosts the body’s immune signaling, helping the immune system respond faster and more effectively.
Additionally, the drug appears to interfere with viral replication, slowing down the virus’s ability to multiply inside the body. These combined effects may explain why patients receiving the treatment showed better outcomes.
According to details highlighted in the study, the drug also demonstrated a strong safety profile, with very few adverse events reported and no deaths linked to its use.
Real World Effectiveness and Acce
ssibility
This
Medical News report highlights that one of the most compelling aspects of inosine pranobex is its accessibility. Unlike newer antiviral drugs that can be expensive or limited in availability, this medication is relatively affordable and widely available in many countries.
Researchers also pointed out that the drug could be particularly valuable in settings where access to advanced COVID-19 therapies is limited or delayed. It may also have potential for early treatment or even preventive use following exposure to the virus.
Limitations and What Comes Next
Despite the promising findings, researchers caution that the study has limitations. It did not include detailed data on patients’ symptoms at the start of infection or results from diagnostic imaging and lab tests. It also did not account for all possible medications or supportive treatments patients may have received.
Still, the consistency of the results across different groups and time periods strengthens the overall conclusions. The researchers emphasize that further clinical trials are needed to confirm these findings and explore additional uses, including potential benefits in long COVID or future viral outbreaks.
Conclusion
The growing body of evidence suggests that inosine pranobex could be a valuable tool in reducing COVID-19 mortality, especially in patients who lack access to advanced treatments. Its ability to enhance immune response, combined with its safety and affordability, makes it a promising candidate for broader use.
However, more rigorous clinical trials are essential before it can be fully integrated into global treatment guidelines, ensuring that its benefits are confirmed and its optimal use clearly defined.
The study findings were published in the peer reviewed International Journal of Infectious Diseases.
https://www.sciencedirect.com/science/article/pii/S1201971226001542
For the latest COVID-19 news, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/coronavirus
https://www.thailandmedical.news/articles/covid19-drugs
Medical Disclaimer: All content published by Thailand Medical News is based on scientific research and is intended for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Readers must not attempt to use, apply, or experiment with any protocols, compounds, or therapies mentioned without first consulting a qualified and licensed medical doctor. Many findings discussed are experimental or preliminary, and only a licensed healthcare professional can determine what is safe and appropriate for an individual’s specific medical condition.
Share
Tweet
Share
